MARKET

QTNT

QTNT

Quotient
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.15
+0.12
+1.99%
Closed 16:00 11/23 EST
OPEN
6.10
PREV CLOSE
6.03
HIGH
6.27
LOW
6.00
VOLUME
503.96K
TURNOVER
--
52 WEEK HIGH
10.38
52 WEEK LOW
2.395
MARKET CAP
621.28M
P/E (TTM)
-5.2345
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company will participate in two upcoming virtual investor conferences. Stifel Virtual Healthcare ConferenceThe Company will be presenting on Tuesday, November 17, 2020 at 8:00am ET.Jefferies Virtual London Healthcare ConferenceThe Company will be presenting on Wednesday, November 18, 2020 at 9:40am ET (2:40pm GMT).Both presentations will be webcast live, and will be available on the investor relations page of the Company’s corporate website at www.quotientbd.com. Webcast replays will be archived on the website for approximately 90 days.About Quotient LimitedBuilding on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.CONTACT: Peter Buhler, Chief Financial Officer – IR@quotientbd.com; +41 22 545 52 26
GlobeNewswire · 11/09 21:05
Quotient Sees FY 2021 Alba Sales Between $32M And $34M
FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020 European field trial for
Benzinga · 11/05 21:45
Quotient Q2 EPS $(0.18) Beats $(0.33) Estimate, Sales $16.07M Beat $7.90M Estimate
Quotient (NASDAQ:QTNT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.33) by 45.45 percent. This is a 56.1 percent increase over losses of $(0.41) per share from the same
Benzinga · 11/05 21:44
Recap: Quotient Q2 Earnings
Benzinga · 11/02 13:27
Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 11/02 12:30
Quotient EPS beats by $0.16, beats on revenue
Quotient (QTNT): FQ2 GAAP EPS of -$0.18 beats by $0.16.Revenue of $16.07M (+104.7% Y/Y) beats by $8.19M.Press Release
Seekingalpha · 11/02 11:01
Notable Earnings Watchlist For Monday, Nov. 2, 2020 Before Market Open: NI, TEN, WM, MPLX, CWH, CLX, AMCX, INGR, MPC, JLL, LCII, CDW, HSIC, EL, QTNT, CNA, ON, LITE
List of notable earnings curated by Benzinga Pro Newsdesk team. The times displayed next to each ticker are estimated report times based on previous report times.  Quotient (QTNT) - 6:00 a.m. EDT CNA Financial
Benzinga · 10/30 20:30
Quotient Limited (NASDAQ:QTNT) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Simply Wall St. · 10/29 17:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QTNT. Analyze the recent business situations of Quotient through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QTNT stock price target is 12.67 with a high estimate of 14.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 155
Institutional Holdings: 92.40M
% Owned: 91.47%
Shares Outstanding: 101.02M
TypeInstitutionsShares
Increased
48
19.35M
New
38
2.08M
Decreased
21
2.99M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.12%
Healthcare Equipment & Supplies
-0.37%
Key Executives
Chairman/Independent Director
Heino von Prondzynski
Chairman/Independent Director
Heino.N.F.M von Prondzynski
Chief Executive Officer/Director
Franz Walt
Chief Financial Officer
Peter Buhler
Chief Operating Officer
Edward Farrell
Treasurer
Ernest Larnach
Other
Jeremy Stackawitz
Independent Director
Isabelle Buckle
Independent Director
Frederick Hallsworth
Independent Director
Catherine Larue
Independent Director
Brian McDonough
Independent Director
Zubeen Shroff
Independent Director
John Wilkerson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About QTNT
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Quotient Ltd stock information, including NASDAQ:QTNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QTNT stock methods without spending real money on the virtual paper trading platform.